|
Daehan New Pharm launches sterilizing and disinfecting agent “Vital Oxide” for the H1N1 flu, expecting annual sales of 10 billion won
2009.11.26
|
|---|
|
Daehan New Pharm Launches “Vital Oxide,” a Disinfectant for H1N1 Flu — Annual Sales Expected to Reach 10 Billion Won
Daehan New Pharm Co., Ltd. (CEO Bae Gun-woo) announced that it will begin full-scale sales of “Vital Oxide” on November 27. The product was developed by the U.S.-based Vital Technologies, registered with the U.S. Environmental Protection Agency (EPA) as a disinfectant, and certified by the National Sanitation Foundation (NSF) as a food-surface sanitizer.
Vital Oxide was the first product registered with the U.S. EPA as being effective in killing the H1N1 influenza virus while remaining safe for human use. The product contains stabilized chlorine dioxide, which works through oxidation by oxygen atoms to eliminate 99.9% of bacteria such as Bacillus and Staphylococcus aureus, as well as E. coli. It is an advanced formula developed by nano-sizing the composition particles, enhancing both penetration and sterilization power. Chlorine dioxide is 100% biodegradable, making this an environmentally friendly product.
Whereas most hand sanitizers containing alcohol can cause dryness and rough skin by stripping away moisture and keratin, Vital Oxide offers high safety with minimal skin irritation. It can be used for hand cleansing and sterilization in households, schools, toys, and vehicles, positioning it as a well-being sterilizing and disinfecting product.
Daehan New Pharm also announced that it will begin full-scale advertising campaigns through newspapers, online platforms, and other mass media starting in December.
Vital Oxide will be available in two types: a portable 50 mL mist-type bottle and a 500 mL spray-type bottle. The company has already secured contracts totaling approximately 1 billion won in sales for December and expects sales to reach 10 billion won next year, based on current trends.
In addition, the company received clinical trial approval for Oseltamivir Capsules (product name: Daehan New Pharm Oseltamivir Capsules), a generic version of Tamiflu for the treatment of H1N1 influenza, following the submission of its bioequivalence study plan to the Korea Food and Drug Administration. |


Home